Wolfe Research analyst Peter Supino downgrades T-Mobile US (NASDAQ:TMUS) from Outperform to Peer Perform.
Merck’s Blockbuster Cancer Drug Keytruda Secures FDA Approval For Biliary Tract Cancer
The FDA approved Merck & Co Inc's (NYSE: MRK) Keytruda, in combination with gemcitabine and cisplatin, for locally advanced unresectable or